PLA2G4F: Potential Drug Target Or Biomarker (G255189)

Target Name: PLA2G4F

NCBI ID: G255189

PLA2G4F: Potential Drug Target Or Biomarker

PLA2G4F (Protamine 2 gene family 4 member F) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the protamine gene family, which is known for the production of proteins that are involved in the production of antibodies and other immune response proteins.

One of the unique aspects of PLA2G4F is its ability to induce an immune response in humans. This protein has been shown to stimulate the production of antibodies in a variety of cell types, including T cells and B cells. This is important because it allows PLA2G4F to be used as a potential drug target or biomarker for a variety of diseases.

One of the potential benefits of PLA2G4F as a drug target is its ability to treat autoimmune diseases. Autoimmune diseases occur when the immune system mistakenly attacks healthy cells or tissues in the body. These diseases can be devastating, and there are currently no effective treatments available for many of them.

PLA2G4F has been shown to be able to treat a variety of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. In animal models, PLA2G4F has been shown to effectively treat these diseases by reducing the production of antibodies that contribute to the immune response.

Another potential use of PLA2G4F as a drug target is its ability to treat cancer. Many cancer treatments, including chemotherapy and radiation therapy, can stimulate an immune response that can help to kill cancer cells. However, this can also cause harm to healthy cells and tissues.

PLA2G4F has been shown to be able to reduce the risk of cancer recurrence in animal models by suppressing the immune response. This suggests that PLA2G4F could be an effective cancer treatment by inhibiting the immune response and reducing the risk of cancer recurrence.

In addition to its potential as a drug target, PLA2G4F has also been shown to be a potential biomarker for a variety of diseases. This is because the production of PLA2G4F is often increased in response to the presence of certain molecules, such as bacteria or viruses. This makes PLA2G4F a potentially useful biomarker for diseases that are characterized by an increase in the production of this protein.

PLA2G4F has been shown to be elevated in the blood of people with a variety of diseases, including cardiovascular disease, diabetes, and neurodegenerative diseases. This suggests that PLA2G4F could be a useful biomarker for these diseases, and that its levels may be a potential diagnostic indicator.

In conclusion, PLA2G4F is a protein that has been shown to have a variety of potential applications as a drug target or biomarker. Its ability to induce an immune response and its potential to treat autoimmune diseases make it an attractive candidate for further research. Additionally, its potential as a biomarker for a variety of diseases makes it an important area of study for researchers. Further research is needed to fully understand the potential applications of PLA2G4F and its potential as a drug or biomarker.

Protein Name: Phospholipase A2 Group IVF

Functions: Has calcium-dependent phospholipase and lysophospholipase activities with a potential role in membrane lipid remodeling and biosynthesis of lipid mediators (PubMed:29158256). Preferentially hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) (PubMed:29158256). Selectively hydrolyzes sn-2 arachidonoyl group from membrane phospholipids, providing the precursor for eicosanoid biosynthesis (PubMed:29158256). In myocardial mitochondria, plays a major role in arachidonate release that is metabolically channeled to the formation of cardioprotective eicosanoids, epoxyeicosatrienoates (EETs) (PubMed:29158256)

More Common Targets